CN1927392A - 复合胶原蛋白滴眼液 - Google Patents
复合胶原蛋白滴眼液 Download PDFInfo
- Publication number
- CN1927392A CN1927392A CN 200510098425 CN200510098425A CN1927392A CN 1927392 A CN1927392 A CN 1927392A CN 200510098425 CN200510098425 CN 200510098425 CN 200510098425 A CN200510098425 A CN 200510098425A CN 1927392 A CN1927392 A CN 1927392A
- Authority
- CN
- China
- Prior art keywords
- collagen
- eye drops
- eyes
- composite collagen
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010035532 Collagen Proteins 0.000 title claims abstract description 70
- 102000008186 Collagen Human genes 0.000 title claims abstract description 70
- 229920001436 collagen Polymers 0.000 title claims abstract description 53
- 239000003889 eye drop Substances 0.000 title claims description 49
- 239000002131 composite material Substances 0.000 title claims description 39
- 229940012356 eye drops Drugs 0.000 title claims description 38
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001699 ofloxacin Drugs 0.000 claims abstract description 9
- 210000002435 tendon Anatomy 0.000 claims abstract description 7
- 230000003115 biocidal effect Effects 0.000 claims description 23
- 239000000644 isotonic solution Substances 0.000 claims description 14
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 229940097572 chloromycetin Drugs 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 abstract description 12
- 208000018380 Chemical injury Diseases 0.000 abstract description 10
- 206010037508 Punctate keratitis Diseases 0.000 abstract description 10
- 230000006378 damage Effects 0.000 abstract description 8
- 208000003464 asthenopia Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 210000005252 bulbus oculi Anatomy 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 abstract 3
- 229940088710 antibiotic agent Drugs 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 230000004520 agglutination Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- NLVFBUXFDBBNBW-UHFFFAOYSA-N 4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol Chemical compound NC1CC(O)C(CN)OC1OC1C(O)C(OC2C(C(N)C(O)C(CO)O2)O)C(N)CC1N NLVFBUXFDBBNBW-UHFFFAOYSA-N 0.000 abstract 1
- -1 alficetin Chemical compound 0.000 abstract 1
- 206010014801 endophthalmitis Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003685 thermal hair damage Effects 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 51
- 230000000694 effects Effects 0.000 description 11
- 206010064996 Ulcerative keratitis Diseases 0.000 description 9
- 201000007717 corneal ulcer Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 201000003827 punctate epithelial keratoconjunctivitis Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000028006 Corneal injury Diseases 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 208000005494 xerophthalmia Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 206010023365 keratopathy Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000162 simple eye Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010077465 Tropocollagen Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100984251A CN100381169C (zh) | 2005-09-08 | 2005-09-08 | 复合胶原蛋白滴眼液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100984251A CN100381169C (zh) | 2005-09-08 | 2005-09-08 | 复合胶原蛋白滴眼液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1927392A true CN1927392A (zh) | 2007-03-14 |
CN100381169C CN100381169C (zh) | 2008-04-16 |
Family
ID=37857623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100984251A Active CN100381169C (zh) | 2005-09-08 | 2005-09-08 | 复合胶原蛋白滴眼液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100381169C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2207598A1 (en) * | 2007-11-16 | 2010-07-21 | Alcon Research, Ltd. | Methods and compositions for treating dry eye |
CN102210856A (zh) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | 一种胶原蛋白滴眼液及其制备方法 |
CN101648004B (zh) * | 2008-08-13 | 2013-11-06 | 北京和润创新医药科技发展有限公司 | 一种用于治疗眼科疾病的药物组合物及其用途 |
CN105985429A (zh) * | 2015-02-09 | 2016-10-05 | 广州创尔生物技术股份有限公司 | 一种具有生物活性的无菌胶原液及其制备方法 |
CN111420036A (zh) * | 2020-04-30 | 2020-07-17 | 广州市醒目医药科技有限公司 | 含有i型胶原和丹参提取物的复合物及制备和应用 |
CN113713086A (zh) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | 一种含有重组iii型人源化胶原蛋白的组合物及其制备方法和用途 |
CN116726151A (zh) * | 2023-03-13 | 2023-09-12 | 河北纳科生物科技有限公司 | 一种用于角膜损伤修复的日抛型滴眼液及其制备方法 |
-
2005
- 2005-09-08 CN CNB2005100984251A patent/CN100381169C/zh active Active
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2207598A1 (en) * | 2007-11-16 | 2010-07-21 | Alcon Research, Ltd. | Methods and compositions for treating dry eye |
CN101648004B (zh) * | 2008-08-13 | 2013-11-06 | 北京和润创新医药科技发展有限公司 | 一种用于治疗眼科疾病的药物组合物及其用途 |
CN102210856A (zh) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | 一种胶原蛋白滴眼液及其制备方法 |
CN102210856B (zh) * | 2011-06-02 | 2012-10-03 | 陕西巨子生物技术有限公司 | 一种胶原蛋白滴眼液及其制备方法 |
CN105985429A (zh) * | 2015-02-09 | 2016-10-05 | 广州创尔生物技术股份有限公司 | 一种具有生物活性的无菌胶原液及其制备方法 |
CN111420036A (zh) * | 2020-04-30 | 2020-07-17 | 广州市醒目医药科技有限公司 | 含有i型胶原和丹参提取物的复合物及制备和应用 |
CN113713086A (zh) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | 一种含有重组iii型人源化胶原蛋白的组合物及其制备方法和用途 |
CN116726151A (zh) * | 2023-03-13 | 2023-09-12 | 河北纳科生物科技有限公司 | 一种用于角膜损伤修复的日抛型滴眼液及其制备方法 |
CN116726151B (zh) * | 2023-03-13 | 2024-04-09 | 河北纳科生物科技有限公司 | 一种用于角膜损伤修复的日抛型滴眼液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100381169C (zh) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10383796B2 (en) | Application and uses of PRG4 and therapeutic modulation thereof | |
CN100381169C (zh) | 复合胶原蛋白滴眼液 | |
US5079236A (en) | Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use | |
US8168599B2 (en) | Composition and method for healing tissues | |
JP2611159B2 (ja) | ヒアルロン酸薬理活性画分、その製造方法および医薬組成物 | |
US20020172712A1 (en) | Antiemetic, anti-motion sustained release drug delivery system | |
US8974803B2 (en) | Injectable biomaterials | |
CN101065106A (zh) | 三元天然聚合物粘弹性组合物 | |
CN1771986A (zh) | 口服关节功能保护剂 | |
CN1660130A (zh) | 含海藻糖和透明质酸的人体润滑剂及其制备方法 | |
CN1927391A (zh) | 胶原蛋白滴眼液 | |
CN102579334A (zh) | 含有玻璃酸钠的滴鼻液及其制备方法 | |
CN104906029A (zh) | 一种鼻腔制剂及其制备方法和应用 | |
CN102188695B (zh) | 一种眼用凝胶组合物 | |
CN102579492A (zh) | 一种含小牛血去蛋白提取物的玻璃酸钠滴眼液及其制备方法 | |
CN105214071A (zh) | 一种纤连蛋白类滴眼液及其制备方法 | |
US20230146680A1 (en) | Method for producing enhanced anti-inflammatory / anti-catabolic agents from autologous physiological fluid | |
KR100963611B1 (ko) | 알긴산류 화합물을 포함하는 점안용 조성물 및 그의제조방법 | |
US20150290248A1 (en) | Fibrous component for health, performance, and aesthetic treatment | |
CN107802597B (zh) | 一种玻璃酸钠组合物及其制备方法和应用 | |
Katual et al. | Advancements in Treatment of Laceration by Chitosan Coated Flexible Liposomes of Mupirocin: A current prospective | |
CN111000974B (zh) | 一种兔奶活性小肽溶液及其提取方法和应用 | |
Napavichayanun | Clinical efficacy of biocellulose wound dressing containing silk sericin and polyhexamethylene biguanide for split-thickness skin graft donor sites | |
Roosyidah et al. | Drug Interactions in Diabetic Ulcer Patients in an Indonesian Private Hospital | |
CN1676134A (zh) | 一种人工泪液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guangzhou Trauer Biotechnology Co., Ltd. Assignor: Tong Gang Contract fulfillment period: 2008.10.18 to 2014.10.18 contract change Contract record no.: 2009440001709 Denomination of invention: Composite collagen eye drops Granted publication date: 20080416 License type: Exclusive license Record date: 20091023 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.10.18 TO 2014.10.18; CHANGE OF CONTRACT Name of requester: GUANGZHOU TRAUER BIOISYSTECH CO., LTD. Effective date: 20091023 |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU TRAUER BIOTECHNOLOGY CO.,LTD Free format text: FORMER OWNER: TONG GANG Effective date: 20100722 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510663 4/F, BUILDING A, NO.17, XIANGSHAN ROAD, SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510663 NO.1, 4/F, BUILDING 17, XIANGSHAN ROAD, GUANGZHOU HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100722 Address after: 510663, No. 4, No. 17, Xiangshan Road, 1 hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee after: Guangzhou Trauer Biotechnology Co., Ltd. Address before: 4 building, A building, No. 17 Xiangshan Road, Luogang District Science City, Guangdong, Guangzhou 510663, China Patentee before: Tong Gang |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 510663, No. 4, No. 17, Xiangshan Road, 1 hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee after: Guangzhou Trauer Biotechnology Co., Ltd. Address before: 510663, No. 4, No. 17, Xiangshan Road, 1 hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee before: Guangzhou Trauer Biotechnology Co., Ltd. |